Several factors including *ITPA* polymorphism influence ribavirin-induced anemia in chronic hepatitis C

Akihito Tsubota, Noritomo Shimada, Hiroshi Abe, Kai Yoshizawa, Rie Agata, Yoko Yamoto, Makiko Ika, Yoshihisa Namiki, Keisuke Nagatsuma, Hiroshi Matsudaira, Kiyotaka Fujise, Norio Tada, Yoshio Aizawa

**Abstract**

**AIM:** To construct formulae for predicting the likelihood of ribavirin-induced anemia in pegylated interferon α plus ribavirin for chronic hepatitis C.

**METHODS:** Five hundred and sixty-one Japanese patients with hepatitis C virus genotype 1b who had received combination treatment were enrolled and assigned randomly to the derivation and confirmatory groups. Single nucleotide polymorphisms at or nearby *ITPA* were genotyped by real-time detection polymerase chain reaction. Factors influencing significant anemia (hemoglobin concentration < 10.0 g/dL at week 4 of treatment) and significant hemoglobin decline (declining concentrations > 3.0 g/dL at week 4) were analyzed using multiple regression analyses. Prediction formulae were constructed by significantly independent factors.

**RESULTS:** Multivariate analysis for the derivation group identified four independent factors associated with significant hemoglobin decline: hemoglobin decline at week 2 \( P = 3.29 \times 10^{-17}, \text{OR} = 7.54 \) (g/dL), estimated glomerular filtration rate \( P = 2.16 \times 10^{-4}, \text{OR} = 0.962 \) (mL/min/1.73 m\(^2\)), rs1127354 \( P = 5.75 \times 10^{-4}, \text{OR} = 10.94 \) and baseline hemoglobin \( P = 7.86 \times 10^{-4}, \text{OR} = 1.50 \) (g/dL). Using the model constructed by these factors, positive and negative predictive values and predictive accuracy were 79.8%, 88.8% and 86.2%, respectively. For the confirmatory group, they were 83.3%, 91.0% and 88.3%. These factors were closely correlated with significant anemia. However, the model could not be constructed, because no patients with rs1127354 minor genotype CA/AA had significant anemia.

**CONCLUSION:** Reliable formulae for predicting the likelihood of ribavirin-induced anemia were constructed. Such modeling may be useful in developing individual tailoring and optimization of ribavirin dosage.
Tsubota A et al. Prediction of ribavirin-induced anemia

Peer reviewers: Dr. Hisato Nakajima, Department of Gastroenterology and Hepatology, The Jikei University School of Medicine, 3-25-8, Nishi-Shinbashı, Minato-ku, Tokyo 105-8461, Japan; Dr. Evelyne Schoerger, CHRU Strasbourg, 3 rue Koeberlé, 67000 Strasbourg, France

Tsubota A, Shimada N, Abe H, Yoshizawa K, Agata R, Yamoto Y, Ika M, Namiki Y, Nagatsuma K, Matsuda H, Fujise K, Tada N, Aizawa Y. Several factors including ITPA polymorphism influence ribavirin-induced anemia in chronic hepatitis C. World J Gastroenterol 2012; 18(41): 5879-5888. Available from: URL: http://www.wjgnet.com/1007-9327/full/v18/i41/5879.htm DOI: http://dx.doi.org/10.3748/wjg.v18.i41.5879

INTRODUCTION
Development and availability of nonstructural (NS) 3 serine protease inhibitors (PIs), such as telaprevir and boceprevir, further improve treatment outcome in combination with pegylated interferon (peg-IFN) α and ribavirin (RBV) for chronic hepatitis C virus (HCV) genotype 1 infection, while the addition of novel antiviral agents increases the frequency and severity of adverse effects (including anemia), medication costs and the complexity of treatment regimens[1-3]. Triple combination therapy with PI, RBV and peg-IFN α will be the first-line treatment for the HCV genotype 1 infection until the establishment of combination with NS3/4A PIs and NS5B polymerase or NS5A inhibitors[4]. Meanwhile, conventional peg-IFN α plus RBV combination will be in demand for easy-to-treat patients who are infected with HCV genotype 2 or 3 or low viral loads and those who contraindicate or are intolerant of triple combination therapy. Accordingly, peg-IFN α plus RBV combination will assume a crucial role in the treatment of HCV infection for the foreseeable future.

In RBV-based treatment, hemolytic anemia is common and one of the major critical adverse effects[1-3,5-7] and therefore makes it difficult for patients to tolerate treatment continuation, resulting in early dose reduction or premature withdrawal that may diminish the treatment efficacy. So far, many factors have been reported to be significantly associated with the significant anemia that could necessitate dose reduction or discontinuation[8-20]. Specifically, host genetic variants at the inosine triphosphatase (ITPA) gene located on chromosome 20 (20p13 region) that lead to ITPA deficiency or low activity have an overwhelming impact on protection against RBV-induced hemolytic anemia, and decrease the need for RBV dose reduction at week 4 of treatment and throughout the treatment course[15-18]. However, there are few reports that provide a convenient prediction model or scoring system for pretreatment screening or early identification of clinically significant anemia that has been defined previously and used generally[19].

To modify RBV dose prior to treatment or during the early treatment phase and continue treatment as long as possible, the present study focused on the construction of a convenient and useful model for predicting the likelihood of clinically significant anemia and quantitative decline in the hemoglobin (Hb) concentration from baseline at week 4 of treatment in peg-IFN α plus RBV treatment for chronic hepatitis C patients infected with HCV genotype 1b. Easy identification of candidates at a high risk for clinically significant anemia may facilitate intensive safety monitoring in combination treatment.

MATERIALS AND METHODS

Study population and protocol
Between 2006 and 2010, 561 chronic hepatitis C patients infected with HCV genotype 1b were consecutively enrolled in this study at Katsushika Medical Center and Kashihara Hospital, The Jikei University School of Medicine, and Shinmatsudo Central General Hospital. Patients received peg-IFN α-2b at a dose of 1.5 µg/kg or peg-IFN α-2a at a dose of 180 µg once weekly and RBV at a dose of 600-1000 mg twice daily for 48 wk. The dose of RBV was adjusted according to body weight (BW); 600 mg for ≤60 kg, 800 mg for >60 kg to ≤80 kg, and 1000 mg for >80 kg. Leading inclusion criteria were chronic hepatitis C that were diagnosed by laboratory, virology and histology; HCV genotype 1b confirmed by the conventional polymerase chain reaction (PCR)-based method; acquisition of written informed consent to the provision of genetic material; availability of genetic DNA for genotyping single nucleotide polymorphisms (SNPs); absence of liver cancer, liver failure or other forms of liver disease; and lack of concurrent treatment with any other antiviral or immunomodulatory agent. The study protocol was conducted in accordance with the provisions of the Declaration of Helsinki and Good Clinical Practice guidelines and was approved by the Institutional Review Boards of all participating sites.

Clinical and laboratory data were assessed at baseline, once weekly during the first 4 wk, and thereafter every 4 wk. As described previously[8], significant anemia was provisionally defined as Hb concentrations of <10.0 g/dL at week 4 of treatment, and significant Hb decline was defined as a decline in Hb concentration of >3.0 g/dL at week 4 of treatment. The reasons for choosing this time point (the end of 4 wk after treatment initiation) were as follows: (1) dose of RBV or peg-IFN was not reduced in most patients, and thus Hb dynamics would not be affected by treatment modification and could be evaluated in an unbiased manner; and (2) Hb decline within the first 4 wk is most prominent throughout the treatment period and reaches a nadir after approximately 4-6 wk[6,19].

At baseline, creatinine clearance (Ccr; mL/min) was estimated by using the Cockcroft-Gault formula[21]: Ccr (for male) = [(140 - age) × BW (kg)]/(72 × Scr) (Scr, serum creatinine; Ccr × 0.85 for female). Estimated glomerular filtration rate (GFR, mL/min/1.73 m²) was...
Virological data were assessed by monitoring serum HCV RNA throughout the treatment. Response (NVR) was defined as persistent presence of undetectable HCV RNA by the end of treatment. Rapid virological response (VR) was defined as VR during treatment but reappearance of HCV RNA during the follow-up period. Nonvirological response (NVR) was defined as persistent presence of HCV RNA throughout the treatment.

### Statistical analysis

Mantel-Haenszel, Pearson $\chi^2$ test or Mann-Whitney test was used to compare frequencies in categorical data or differences in continuous data between two groups, respectively. Time-course changes in Hb decline from baseline were evaluated by using repeated measures analysis of variance. Possible variables influencing significant anemia and significant Hb decline included baseline characteristics (Table 1). Variables that reached significance in univariate comparisons were subsequently entered into multiple logistic regression analysis using forward and backward stepwise selection method to identify significantly independent factors associated with each anemic event. Based on the final-step results, score models were constructed to identify the best fitness of the model. Split-group validation was used to compare the performance of different models. The presence or absence of serum HCV RNA was assessed using a qualitative PCR assay (AmpliCyclic HCV version 2.0). Virological response (VR) was defined as undetectable HCV RNA by the end of treatment. Rapid virological response and slow virological response (SVR) were defined as undetectable HCV RNA at week 4 of treatment and 24 wk post-treatment. Viral relapse was defined as VR during treatment but reappearance of HCV RNA during the follow-up period. Nonvirological response (NVR) was defined as persistent presence of HCV RNA throughout the treatment.

| Variable          | Overall cohort (n = 561) | Derivation group (n = 374) | Confirmatory group (n = 187) |
|-------------------|--------------------------|---------------------------|-----------------------------|
| Demographic feature |                          |                           |                             |
| Age (yr)          | 59.1 ± 10.9              | 59.1 ± 10.8               | 59.5 ± 11.3                 |
| Sex (female/male) | 302/259                  | 201/173                   | 101/86                      |
| Weight (kg)       | 59.8 ± 11.4              | 59.9 ± 11.5               | 58.5 ± 10.9                 |
| BMI (kg/m²)       | 22.3 ± 3.3               | 23.2 ± 3.4                | 23.2 ± 3.2                  |
| Height (cm)       | 160.3 ± 9.0              | 160.4 ± 9.1               | 158.5 ± 8.7                 |
| Waist (m²)        | 1.62 ± 0.18              | 1.62 ± 0.18               | 1.59 ± 0.18                 |
| Laboratory data   |                          |                           |                             |
| ALT (IU/L)        | 63 ± 54                  | 63 ± 56                   | 58 ± 47                     |
| GGT (IU/L)        | 58 ± 63                  | 56 ± 60                   | 58 ± 72                     |
| Albumin (g/dL)    | 4.1 ± 0.4                | 4.1 ± 0.4                 | 4.1 ± 0.3                   |
| Creatinine (mg/dL)| 0.70 ± 0.16              | 0.70 ± 0.17               | 0.70 ± 0.17                 |
| WBC count         | 5.0 ± 1.5                | 5.0 ± 1.5                 | 5.1 ± 1.4                   |
| Hemoglobin (g/dL) | 13.7 ± 1.5               | 13.7 ± 1.5                | 13.8 ± 1.3                  |
| Platelet count    | 16.7 ± 5.7               | 16.5 ± 5.7                | 17.0 ± 6.2                  |
| Estimated calculation value |                 |                           |                             |
| Ccr (mL/min)      | 91.8 ± 27.9              | 91.6 ± 28.0               | 87.9 ± 25.6                 |
| GFR (mL/min/1.73 m²)| 77.5 ± 16.6             | 79.6 ± 17.0               | 78.2 ± 15.9                 |
| CL/F (L/h)        | 11.3 ± 5.4               | 11.2 ± 5.3                | 10.9 ± 5.1                  |
| Liver histopathology |                        |                           |                             |
| Stage of fibrosis |                          |                           |                             |
| 0-1/2/3-4         | 221/131/161             | 146/89/107                | 75/42/54                    |
| Grade of inflammation |                       |                           |                             |
| 1/2/3             | 267/222/19               | 170/156/14                | 97/66/5                     |
| SNP genotype      |                          |                           |                             |
| rs1127354 CC/CA/AA| 431/114/16              | 289/75/10                 | 142/39/6                    |
| rs6051702 AA/AC/CC| 388/158/15              | 260/104/10                | 128/54/3                    |
| Treatment         |                          |                           |                             |
| Ribavirin dosage  | 11.4 ± 1.5               | 11.3 ± 1.9                | 11.4 ± 1.9                  |
| Peg-IFN α-2a/-2b  | 82/479                  | 52/322                    | 30/157                      |
| Viral load        | 6.2 ± 0.8                | 6.2 ± 0.8                 | 6.2 ± 0.8                   |
| (log10 IU/mL)     |                          |                           |                             |

BMI: Body mass index; BSA: Body surface area; ALT: Alanine transaminase; GGT: γ-glutamyl transpeptidase; WBC: White blood cell; GFR: Glomerular filtration rate; SNP: Single nucleotide polymorphism; Peg-IFN: Pegylated interferon.

Briefer formula proposed by the Japanese Society of Nephrology: GFR (for male) =194 × Scr$^{1.097} ×$ Age$^{-0.287}$ (GFR × 0.739 for female). Apparent clearance of ribavirin (CL/F, L/h) was determined as follow$^{9}$: CL/F = 32.3 × BW × (1 - 0.0094 × age) × (1 - 0.287 × gender)/Scr (gender = 0 for male and 1 for female; Scr is in µmol/L). All liver biopsy specimens were reviewed by using the established ranking system for staging of fibrosis and grading of necroinflammation activity with some modification$^{23}$. Virological data were assessed by monitoring serum HCV RNA levels every 4 wk during and off treatment. Viral loads were measured using a quantitative PCR assay (AmpliCyclic HCV Monitor version 2.0 or AmpliCyclic HCV version 2.0; Roche Diagnostics, Basel, Switzerland).
singed to the derivation group and 33.3% (187 patients) to the confirmatory group. The reproducibility of the resulting model based on data from the derivation group was assessed with data from the validation group. Receiver operating characteristic (ROC) curves were generated with every cut-off point of predicted probability of significant Hb decline corresponding to each Hb decline at week 2. For a balanced optimization of both sensitivity and false-positive rate [= (1 - specificity)], an optimal cut-off point value was determined by maximizing Youden's index (= sensitivity + specificity - 1). The area under the ROC curve (AUC) was calculated to assess the degree of discrimination provided by the two parameters. To formulate a predictive value of quantitative Hb decline at weeks 2 and 4, the association between Hb decline and baseline variables was also analyzed using multiple linear regression analysis. The fitness of the model was evaluated by using values of R and R² and Durbin-Watson test. The correlation between predictive and measured values in Hb decline was assessed by Spearman's ρ. All P values for statistical tests were two tailed and values < 0.05 denoted the presence of a statistically significant difference. All data analyses were performed using the SPSS statistical package for Windows, version 17.0 (SPSS, Chicago, IL, United States).

RESULTS

Patient profiles and treatment-induced anemia

Baseline characteristics of the study population are summarized in Table 1. There were no significant differences in the patient profiles between the groups. The mean (SD) and median (25th to 75th quartiles) of Hb decline from baseline at week 2 and 4 of treatment are shown in Table 2. The changes at each time point were not statistically different between the groups. Significant Hb decline was observed in 113 of 374 (30%) derivation group patients and 58 of 187 (31%) confirmatory group patients. Significant anemia was observed in 51 of 374 (14%) patients and 30 of 187 (16%) patients, respectively. Incidence of these anemic events was similar between the groups. Most of the patients complained of dyspnea on effort, easy fatigability or lightheadedness. None received erythropoiesis-stimulating agents throughout the treatment period.

Of the overall patients, 255 (45%) achieved SVR, 165 (29%) had VR with relapse, and 141 (25%) showed NVR. Of the 374 derivation group patients, SVR was 45% (167 patients), VR with relapse was 30% (111 patients) and NVR was 26% (96 patients). Of the 187 confirmatory group patients, they were 47% (88 patients), 29% (54 patients) and 24% (45 patients), respectively. Treatment outcome was almost equal among the overall cohort and split groups.

Baseline factors associated with significant Hb decline

To construct the prediction model for significant Hb decline, baseline variables were statistically analyzed in the derivation group (Table 3). Patients who showed significant Hb decline were more likely to be male (P = 0.0163), have higher BW (P = 0.00518), higher body mass index (BMI; P = 0.00593), larger body surface area (BSA; P = 0.0139), higher albumin (P = 0.00688), higher creatinine (P = 4.71 × 10⁻³), higher Hb (P = 7.75 × 10⁻³), lower GFR (P = 5.69 × 10⁻³), and SNP rs1127354 major
Baseline factors associated with significant anemia

Female (P = 0.00896) and older (P = 0.0443) patients, and those with lower albumin (P = 0.0197), lower white blood cell count (P = 0.0226), lower baseline Hb (P = 5.34 × 10^(-13)), lower Ccr (P = 1.06 × 10^(-8)), lower GFR (P = 2.69 × 10^(-5)), lower Cl/F (P = 6.59 × 10^(-5)), lower BW (P = 0.00309), smaller BSA (P = 0.0254), and rs1127354 major genotype CC (P = 2.76 × 10^(-5)) were more likely to have significant anemia than those who did not. In multiple logistic regression analysis, the model could not be constructed by these variables, because no patients with rs1127354 minor genotype CA/AA suffered from significant anemia in this study population (Figure 1). All patients with significant anemia had rs1127354 major genotype CC. When SNP rs1127354 was excluded from the multivariate analysis, baseline Hb (P = 1.67 × 10^(-13), OR = 0.376 (g/dL), 95%CI: 0.274-0.517) and GFR (P = 0.00233, OR = 0.962 (mL/min/1.73 m^2), 95%CI: 0.938-0.986) were significantly independent variables. Significant anemia was not associated with treatment outcome in the overall cohort [SVR, 31% (25/81); VR, 36% (29/81); and NVR 33% (27/81)] or split groups.

Figure 1 shows the incidence rates of significant anemia and significant Hb decline in the overall cohort according to the three significantly independent factors. Specifically, SNP rs1127354 had an overwhelming impact on the anemic events. In 431 patients with major genotype CC, significant anemia and significant Hb decline developed in 81 (19%) and 168 (39%) patients, respectively. In contrast, none (0%) and three (2%) of 130 patients with minor genotype CA/AA showed each anemic event, respectively, as described above. Positive predictive values of SNP rs1127354 alone for the likelihood of significant anemia and significant Hb decline were 14.3% and 39.1%, respectively. Negative predictive values were 100% and 97.7%, respectively. Values of predictive accuracy were 35.7% and 53.5%, respectively. Figure 2 depicts time-course changes in qualitative Hb decline from baseline according to SNP rs1127354 genotypes. The SNP genotype significantly influenced Hb decline at week 2 as well as week 4 (P = 5.437 × 10^(-5)).

Contribution of Hb decline at week 2 of treatment

Hb decline from baseline at week 2 of treatment, an on-treatment factor, significantly influenced significant Hb decline (P = 1.96 × 10^(-13)). An ROC curve was depicted to identify an optimal cut-off point for prediction of significant Hb decline by using Hb decline at week 2.
Figure 2  Hemoglobin decline from baseline at week 2 and 4 of treatment according to the inosine triphosphatase single nucleotide polymorphism rs1127354 genotypes. Bars within boxes denote the median value of hemoglobin (Hb) decline from baseline. The boxes and the lower and upper bars represent the 25th to 75th percentiles, and the 10th and 90th percentiles, respectively. The single nucleotide polymorphism genotype significantly influenced Hb decline at week 2 and 4 ($P = 5.437 \times 10^{-3}$ in repeated measures analysis of variance).

Figure 3  Receiver operating characteristic curves generated with every cut-off point of predicted probability of significant hemoglobin decline (> 3.0 g/dL at week 4 of treatment) corresponding to each hemoglobin decline from baseline at week 2 of treatment. The area under the curve was 0.913 (95% confidence interval: 0.885-0.941, $P = 4.08 \times 10^{-4}$). When the sensitivity and false-positive rate were 0.844 and 0.131, the Youden’s index value of 0.713 was maximal. The optimal cut-off point of hemoglobin decline at 2 wk was 1.45 g/dL.

When this variable, together with baseline variables, was incorporated into multiple logistic regression analysis to generate a statistic model for predicting significant Hb decline, the re-performed analysis using the derivation group data identified four significantly independent variables: Hb decline at week 2 [$P = 3.29 \times 10^{-9}$, OR = 7.54 (g/dL)], GFR [$P = 2.16 \times 10^{-4}$, OR = 10.94, 95%CI: 2.80-42.71], baseline Hb [$P = 7.86 \times 10^{-4}$, OR = 1.50 (g/dL)], 95%CI: 1.18-1.90]. The model was expressed as: $\hat{y} = -8.285 - 2.020 \times \text{Hb decline at week 2} - 2.393 \times \text{SNP rs1127354 (where genotype CC was 1 and CA/AA was 0) + 0.405 \times \text{baseline Hb.}}$. $P$ values were 0.587 and 1.59 \times 10^{-35}$ in the Hosmer-Lemeshow test and likelihood-ratio $\chi^2$ test, respectively. Positive and negative predictive values and predictive accuracy were 83.3%, 91.0% and 88.3% in the confirmatory group, and 81.3%, 89.0% and 86.7% in the overall cohort.

**Prediction of Hb decline value**

To predict qualitative Hb decline value at week 4 of treatment, the multiple linear regression model was constructed using data from the derivation group. The statistic model was expressed as: $\hat{y} = 0.784 - 0.748 \times \text{Hb at week 2} - 0.039 \times \text{GFR + 2.80-42.71, baseline Hb [P = 7.86 \times 10^{-4}, OR = 1.50 (g/dL)}$, 95%CI: 1.18-1.90]. The model was expressed as: $\hat{y} = -8.285 - 2.020 \times \text{Hb decline at week 2} - 2.393 \times \text{SNP rs1127354 (where genotype CC was 1 and CA/AA was 0) + 0.405 \times \text{baseline Hb.}}$. $P$ values were 0.587 and 1.59 \times 10^{-35}$ in the Hosmer-Lemeshow test and likelihood-ratio $\chi^2$ test, respectively. Positive and negative predictive values and predictive accuracy were 79.8%, 88.8% and 86.2%, respectively. These values were 83.3%, 91.0% and 88.3% in the confirmatory group, and 81.3%, 89.0% and 86.7% in the overall cohort.
tively weak (Spearman’s $\rho = 0.566$, $P = 2.41 \times 10^{-17}$).

**DISCUSSION**

As mentioned in the introduction section, peg-IFN $\alpha$ plus RBV combination will be in demand for the foreseeable future. Patients at a high risk of developing RBV-induced hemolysis will expose themselves to a more increased risk for treatment-induced anemia in triple combination treatment. Identifying such high-risk patients and predicting the severity of anemia in individuals may provide an early decision to commence treatment with normal or reduced dosage and to keep the dose reduction to a minimum to lessen the disadvantages of anemia with adequate exposure to RBV continuing. To date, many studies have proposed factors that could influence the probability of clinically significant anemia in RBV-based treatment: age, sex, race, pre-existing cirrhosis, baseline Hb concentration, Ccr, CL/ $\rho$, drug exposure, plasma RBV concentration, Hb decline at week 2 of treatment, and SNPs at the $ITPA$ [15-18], $C20orf194$ [15] and nucleoside transporter genes [19]. However, the definition of anemia or end point of analysis varied a little among previous studies, possibly leading to alteration of significant predictors. Despite these useful predictors, there is no convenient prediction model or formula for estimating the likelihood of clinically significant anemia that has been defined previously and used generally [15]. This study provided relevant numerical expressions constructed by independent variables for predicting the differentially defined anemia: Hb concentration $<$ 10.0 g/dL (significant anemia) and a decline in Hb concentration $>$ 3.0 g/dL (significant Hb decline) at week 4 of treatment and qualitative Hb decline at week 2 and 4. This is believed to be the first report to construct the prediction models by using reliable factors: the $ITPA$ SNP rs1127354, baseline Hb concentration, estimated GFR, and quantitative Hb decline at week 2 of treatment, irrespective of the different definitions of anemia. The significant baseline factors that were shown in this study appear to influence treatment-induced anemia in triple combination treatment (under investigation, data not shown).

Two functional $ITPA$ variants conferring ITPA deficiency or reduced activity are known to contribute most to protection against RBV-induced hemolytic anemia [11-18]. Inosine triphosphate (ITP) is hydrolyzed by ITPA to inosine monophosphate. Therefore, ITPA deficiency or low activity causes the accumulation of ITP in red blood cells (RBCs) [24-26]. The accumulated ITP may compete with the accumulated triphosphate form of RBV that could mediate oxidative damage to the RBC membrane and extravascular destruction [25-27], thereby protecting RBCs against RBV-induced hemolysis. As also shown in this study, one functional SNP rs1127354 is prominently associated with differentially defined anemia. Of note, however, the SNP was not always a factor of the top significance. The combined ITPA activity variable with another functional SNP rs7270101 is a stronger determinant of anemia than either $ITPA$ SNP alone in European-Americans [20], whereas rs7270101 is not polymorphous in the Japanese population as registered in the HapMap database and reported by others [17,18,23]. One SNP, rs6051702 at the $C20orf194$ located near the $ITPA$, linked to the $ITPA$ SNPs, also confers protection against anemia in European-Americans [15], while the association was statistically significant but weak in one Japanese cohort [18]. This Japanese study population showed no significant association (Table 3), supporting that rs1127354 is a single causal variant responsible for protection against anemia in the Japanese genetic cohort [15].

Certainly, the $ITPA$ SNP rs1127354 minor variant A is a strong protective allele for anemia. In this overall cohort, none (0%) and three (3%; who had genotype CA) of patients with minor variant A had significant anemia and significant Hb decline, respectively (Figure 1). Therefore, negative predictive value of minor variant A was 100% and 97.7%, respectively. The noticeable distinction was in excellent agreement with other studies [15,18]. With respect to the likelihood of these anemic events, patients with minor variant A may be monitored less intensively and recommended to receive normal RBV doses, even in patients with relatively low baseline Hb, or more aggressive dose escalation strategies irrespective of baseline Hb. It is noteworthy that genotype AA patients with predicted ITPA deficiency, including seven patients with baseline Hb $<$ 13.0 g/dL (range, 11.7-12.9 g/dL), showed no or little change in the Hb concentration (data not shown), although the number was small.

As shown in this study and another study [28], however, only 25% of the Japanese population has minor variant A. The remaining 75% have major genotype CC. Positive predictive values of major genotype CC alone for significant anemia and significant Hb decline were low (14.3% and 39.1%, respectively), and values of predictive accuracy were low (35.7% and 53.9%, respectively). The range of Hb decline varied widely among individuals with genotype CC, indicating that some of them showed little or no change in Hb decline. Even in minor genotype CA carriers, it also varied widely and was similar to that of genotype CC patients (Figure 2). These findings strongly suggest that any factors other than the strong predictor $ITPA$ SNP could affect hemolysis positively or negatively. Therefore, it is highly unlikely that the $ITPA$ SNP (except genotype AA) is used alone to determine clinical decision making for treatment modification. In fact, several factors independently and strongly influenced treatment-induced anemia as well as the $ITPA$ SNP in this study.

The clearance rate of RBV from the body is of critical importance for influencing treatment outcome and RBV-induced anemia, because the clearance parameters, such as CL/F and Ccr, reflect plasma/serum RBV con-
concentrations at week 4 of treatment, which means the steady phase of treatment. Higher or lower values of the parameters are correlated closely with lower or higher plasma/serum concentrations, respectively. Higher plasma/serum concentrations lead to an increased risk for progression of anemia as well as the higher probability of achieving SVR. Indeed, this study confirmed that the clearance rate is associated significantly and independently with RBV-induced anemia irrespective of the different definitions. This study also analyzed which of three parameters estimated by the formulae were the most stable for predicting clinically significant anemia. These formulae are composed by age, sex, BW and serum creatinine. Age and sex have been reported to affect treatment-induced anemia and dose reduction, and could reflect reactivity to treatment, tolerance and pharmacological metabolism. Japan is one of the countries with the longest living people and the world’s fastest aging society, therefore, the clearance rate should especially be taken into account in RBV-based treatment of Japanese patients. The reason that estimated GFR remained an independent factor in the final model may be that the formula has been built up based on data from the Japanese population.

Higher baseline Hb concentration was significantly associated with the likelihood of significant Hb decline. Conversely, lower baseline Hb concentration was linked to significant anemia. These findings may be a matter of course. However, most of this study population received treatment without RBV dose reduction as scheduled, suggesting that kinetics of Hb decline within the first 4 wk of treatment might be delayed in patients with lower baseline Hb concentration. A certain threshold of Hb concentration might limit the progression of anemia independent of baseline Hb concentration. At least in Japanese patients, the two different definitions of anemia, significant Hb decline and significant anemia, should be separately analyzed and discussed.

In this multivariate analysis, qualitative Hb decline at week 2 of treatment was most highly predictive of significant Hb decline, compared to the strong predictor ITPA SNP rs1127354 and other baseline factors. Previous studies have shown that Hb decline of 2.0 g/dL at week 2 of treatment was predictive of Hb concentration < 10 g/dL or < 8.5 g/dL during the treatment. In another study, Hb decline of 1.5 g/dL at week 2 was predictive of Hb decline ≥ 2.5 g/dL at week 4. In this ROC analysis, the best cutoff value for Hb decline at week 2 was 1.45 g/dL. Taken together, Hb decline at week 2 is an excellent early predictor of subsequent Hb decline and could identify candidates for early intervention to maintain RBV dosing and adequate exposure. Indeed, the formula including this on-treatment variable improved positive and negative predictive values and predictive accuracy for significant anemia and significant Hb decline. When considered along with other independent baseline factors predictive of qualitative Hb decline at week 4, the final model yielded high significant values that represented goodness of fit. Using such a timely on-treatment variable and formula, more exact identification of patients prone to clinically significant anemia, early intervention with RBV dose reduction, and more careful monitoring may be indicated to reduce anemia-related adverse effects and avoid premature discontinuation of RBV.

ITPA SNP rs1127354, baseline Hb concentration and estimated GFR influenced Hb decline at week 2 significantly and independently, as well as that at week 4. However, it appears to be difficult to predict qualitative Hb decline at week 2 by using the multiple linear regression model. The point for attention is that the models and formulae did not perfectly predict the likelihood of the anemia, strongly suggesting the possibility that other unidentified factors associated with early occurring anemia might be lost, such as rare SNPs, brittleness of the RBC membrane against intracellular triphosphate form of RBV, or intracellular concentration of ITP.

In conclusion, convenient formulae for qualitatively or quantitatively predicting the likelihood of differentially defined anemia could be generated by significant independent factors in RBV-based treatment for chronic HCV infection. Such trial modeling may be useful in guiding clinical decision making on treatment modification: identifying the predisposition to develop RBV-induced anemia before treatment initiation or at the early treatment phase, and developing the individual tailoring and optimization of RBV dosage to maximize the treatment efficacy and minimize RBV-related adverse effects.

ACKNOWLEDGMENTS
We thank physicians and staff members at Shinmatsudo Central General Hospital and Katsushika Medical Center and Kashiwa Hospital, The Jikei University School of Medicine for their help.

COMMENTS

Background
In ribavirin (RBV)-based treatment for chronic hepatitis C, hemolytic anemia is a major adverse effect and makes it difficult to continue treatment as scheduled. Many factors have been reported to influence clinically significant anemia that could modify or discontinue treatment. However, the definition of anemia or end point of analysis varied somewhat among studies, leading to alteration of significant predictors. Despite these useful predictors, there is no convenient prediction model for estimating the probability of clinically significant anemia.

Research frontiers
Host genetic variation at the inosine triphosphatase (ITPA) gene that leads to ITPA deficiency or low activity are known to contribute greatly to protection against RBV-induced hemolytic anemia. However, it is highly unlikely that the ITPA single nucleotide polymorphism (SNP) alone is used to determine clinical decision making for treatment modification. Any factors other than the strong predictor ITPA SNP could affect hemolytic anemia positively or negatively.

Innovations and breakthroughs
This study provided relevant numerical expressions constructed by using significantly independent factors for predicting the differentially defined anemia. The reliable factors were the ITPA SNP rs1127354, baseline hemoglobin (Hb) concentration, estimated glomerular filtration rate and quantitative Hb decline.
at week 2 of treatment, irrespective of the different definitions of anemia. These factors independently and strongly influenced RBV-induced anemia, as well as the ITFA SNP. The ITFA SNP was not always a factor of major significance.

**Applications**

Such modeling may be useful in guiding clinical decision making on treatment modification: more exactly identifying candidates at a high risk for clinically significant anemia or predicting the severity of anemia in individuals before treatment initiation or at the early treatment phase, and developing the individual tailoring and optimization of RBV dosage to maximize the treatment efficacy and minimize RBV-related adverse effects with adequate exposure to RBV continuing.

**Peer review**

Pegylated interferon plus RBV still assumes an important role in the treatment of chronic hepatitis C. The manuscript is well written and the study has investigated a crucial point of anti-HCV treatment. Interestingly, the authors observed a significant Hb decline and significant anemia, respectively, and showed that factors associated with anemia differed according to the definitions.

**REFERENCES**

1. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. *N Engl J Med* 2009; 360: 1827-1838.

2. McHutchison JG, Manns MP, Muir AJ, Tauratt NA, Jacobson IM, Afhdal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceglie AM. Telaprevir for previously treated chronic HCV infection. *N Engl J Med* 2010; 362: 1292-1303.

3. Kwok PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury J, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alf-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. *Lancet* 2010; 376: 705-716.

4. Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. *Liver Int* 2012; 32 Suppl 1: 88-102.

5. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alf-2b plus ribavirin compared with interferon alf-2b and ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001; 358: 958-965.

6. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alf-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002; 347: 975-982.

7. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *A m Intern Med* 2004; 140: 346-355.

8. Jen JF, Glue P, Gupta S, Zambas D, Hajjan G. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. *Ther Drug Monit* 2000; 22: 555-565.

9. Kumar N, Chatelut E, Manolis E, Lafont T, Izopet J, Rostaing L. Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. *Am J Kidney Dis* 2004; 43: 140-146.

10. Lindahl K, Schwarz R, Bruchfeld A, Stähle L. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anemia. *J Viral Hepat* 2004; 11: 84-87.

11. Takai S, Tsutoba A, Hosaka T, Akuta N, Someya T, Kobayashi M, Suzuki F, Suzuki Y, Saitou S, Arase Y, Ikeda K, Kumada H. Factors contributing to ribavirin dose reduction due to anemia during interferon alf-2a and ribavirin combination therapy for chronic hepatitis C. *J Gastroenterol Hepatol* 2004; 19: 1312-1317.

12. Snoeck E, Wade JR, Duff F, Lamb M, Jorga K. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alf-2a (40KD) plus ribavirin. *Br J Clin Pharmacol* 2006; 62: 699-709.

13. Reau N, Hadziyannis SJ, Messinger D, Fried MW, Jensen DM. Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alf-2a (40KD) plus ribavirin. *Am J Gastroenterol* 2008; 103: 1981-1988.

14. Ferray J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shiana KV, Little LD, Qiu P, Bertelson AH, Watson M, Warner A, Muir AJ, Brass C, Albrecht J, Sulkowski M, McHutchison JG, Goldstein DB. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. *Nature* 2010; 464: 405-408.

15. Thompson AJ, Ferray J, Patel K, Tillmann HL, Naggie S, Ge D, Urban TJ, Shiana KV, Muir AJ, Fried MW, Afhdal NH, Goldstein DB, McHutchison JG. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. *Gastroenterology* 2010; 139: 1181-1189.

16. Ochi H, Maekawa T, Abe H, Hayashida Y, Nakano R, Kubo M, Tsunoda T, Hayes CN, Kumada H, Nakamura Y, Chayama K. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy—a genome-wide study of Japanese HCV virus patients. *Gastroenterology* 2010; 139: 1190-1197.

17. Sakamoto N, Tanaka Y, Nakagawa M, Yatsushahi H, Nishiguchi S, Enomoto N, Azuma S, Nishimura-Sakurai Y, Kakimura S, Nishida N, Tokunaga K, Honda M, Ito K, Mizokami M, Watanabe M. ITPA gene variant protects against anemia induced by pegylated interferon-alfa-2a and ribavirin therapy for Japanese patients with chronic hepatitis C. *Hepatol Res* 2010; 40: 1063-1071.

18. Doehringer A, Hofmann WP, Schlochter C, Zeuzem S, Sarrazin C, Berg T, Muller T, Herrmann E, Geisslinger G, Lotzsch J. Role of nucleoside transporters SLc28A2/3 and SLc29A1/2 in anemia induced by pegylated interferon alf-2a and ribavirin therapy for Japanese patients with chronic hepatitis C. *Hepatol Res* 2010; 40: 1063-1071.

19. Merck KGaA. Telaprevir for previously treated chronic hepatitis C patients treated with peginterferon alf-2a (40KD) plus ribavirin. *B r J Clin Pharmacol* 2006; 62: 699-709.

20. Hiramatsu N, Kurokawa M, Sakamoto N, Iwasaki M, Saka moto M, Suzuki Y, Sugachia F, Tamori A, Kakimura S, Matsuura K, Izumi N. Pretreatment prediction of anemia progression by pegylated interferon alf-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis. *J Gastroenterol Hepatol* 2011; 26: 1111-1119.

21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron* 1976; 16: 31-41.

22. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. *Hepatology* 1994; 19: 1513-1520.

23. Tsutoba A, Shimada N, Yosihzawa K, Furuhata T, Agata R, Yumoto Y, Abe H, Ika M, Namiki Y, Chiba K, Fujise K, Tada N, Aizawa Y. Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients. *Liver Int* 2012; 32: 826-836.
Tsubota A et al. Prediction of ribavirin-induced anemia

24 Fraser JH, Meyers H, Henderson JF, Brox LW, McCoy EE. Individual variation in inosine triphosphate accumulation in human erythrocytes. Clin Biochem 1975; 8: 353-364

25 Bierau J, Lindhout M, Bakker JA. Pharmacogenetic significance of inosine triphosphatase. Pharmacogenomics 2007; 8: 1221-1228

26 Stepchenkova EI, Tarakhovskaya ER, Spitter K, Frahm C, Menezes MR, Simone PD, Kolar C, Marky LA, Borgstahl GE, Pavlov YI. Functional study of the P32T ITPA variant associated with drug sensitivity in humans. J Mol Biol 2009; 392: 602-613

27 De Franceschi L, Fattovich G, Turrini F, Ayi K, Brugnara C, Manzato F, Noventa F, Stanzial AM, Solero P, Corrocher R. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000; 31: 997-1004

28 Tsubota A, Hirose Y, Izumi N, Kumada H. Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection. Br J Clin Pharmacol 2003; 55: 360-367

29 Sezaki H, Suzuki F, Kawamura Y, Yatsuji H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, Kumada H. Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci 2009; 54: 1317-1324

S-Editor Wu X  L-Editor Kerr C  E-Editor Zhang DN